ORMP · Oramed Pharmaceuticals Inc. · Financials
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $2M | — | $1.34M | $2.7M | $2.7M | $2.71M | $2.7M | $2.45M | $2.46M | $641K | — | — | — | — | |
| — | $1.99M | — | — | — | — | $90K | $90K | — | $187K | $490K | — | — | — | — | |
| — | $13K | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | 0.65% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $4.74M | $6.38M | $6.32M | $8.97M | $27.64M | $20.99M | $10.24M | $13.52M | $11.98M | $10.28M | $7.71M | -$4.78M | $3.28M | $2.27M | $1.68M | |
| $9.79M | $8.72M | $6.46M | $8.43M | $13.81M | $5.94M | $4.23M | $3.72M | $4.08M | $2.76M | $2.45M | -$2.6M | $2.63M | $2.03M | $1.2M | |
| — | — | — | — | — | — | — | — | — | — | — | — | $6000 | — | — | |
| -$14.52M | -$15.09M | -$12.78M | -$15.77M | -$40.6M | -$24.22M | -$11.76M | -$14.63M | -$13.53M | -$10.77M | -$10.01M | $7.38M | -$5.91M | -$4.3M | -$2.88M | |
| — | -754.4% | — | -1176.79% | -1501.96% | -896.15% | -433.84% | -541.29% | -552.35% | -438.56% | -1561.62% | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | -$5.9M | — | — | |
| — | — | $853K | $2.04M | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | $10K | — | — | — | — | — | — | — | — | — | — | — | |
| $225.24M | $89.45M | -$2.29M | $22.89M | $2.93M | — | — | — | — | — | — | — | — | — | — | |
| $220.28M | $75.32M | -$15.92M | $5.09M | -$37.66M | — | -$11.51M | -$14.06M | -$12.73M | -$10.08M | -$9.63M | $7.23M | -$5.69M | -$4.44M | -$3.25M | |
| $45.41M | $11.31M | $3.18M | — | $100K | — | $300K | $300K | $400K | $400K | $1.34M | $1000 | $4000 | -$205.06K | $90.22K | |
| $174.87M | $64.05M | -$19.06M | $5.09M | -$36.56M | -$22.99M | -$11.51M | -$14.36M | -$12.73M | -$10.48M | -$10.96M | $7.23M | -$5.7M | -$4.23M | -$3.34M | |
| — | 3202.5% | — | 379.7% | -1352.61% | -850.5% | -424.76% | -531.08% | -519.68% | -426.71% | -1710.45% | — | — | — | — | |
| — | -$34K | -$43K | $437K | -$1.2M | — | — | — | — | — | — | — | — | — | — | |
| — | $63.24M | -$19.06M | — | -$36.56M | $22.99M | $11.51M | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | $22.24M | $11.51M | -$14.36M | -$12.43M | -$10.19M | -$11.42M | $7.13M | -$5.55M | -$3.93M | — | |
| USD/shares | $4.24 | $1.53 | -$0.48 | $0.14 | -$0.94 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | $4.13 | $1.50 | -$0.48 | $0.14 | -$0.94 | — | — | — | — | — | — | — | — | — | — |
| shares | — | 41.4M | 40.85M | 40.32M | 39M | 28.47M | 20.53M | 17.45M | 14.88M | 13.31M | 12.62M | 10.82M | 9.24M | 7.21M | — |
| shares | — | 42.42M | 40.85M | 40.57M | 39M | 28.47M | 20.53M | 17.45M | 14.88M | 13.31M | 12.62M | 10.82M | 9.24M | 7.21M | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2024–FY2025: $7.23M in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 311 similar-size Biotechnology companies (of 536 listed).